| abstract |
Novel modulators comprising antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. In certain embodiments, for example, isolated DLL3 modulators are provided. In certain embodiments, the DLL3 modulator may comprise an antibody or an immunoreactive fragment thereof. In another embodiment, the antibody or immunoreactive fragment thereof may comprise a monoclonal antibody. In another embodiment, the monoclonal antibody may be selected from the group consisting of a chimeric antibody, a humanized antibody and a human antibody. |